May 7 |
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
|
May 2 |
Palisade Bio looks to raise $4M in private placement
|
May 2 |
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
|
May 1 |
Palisade Bio stock rallies 50% premarket on colitis drug update
|
May 1 |
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
|
Apr 23 |
Dow Jumps Over 200 Points; US Services PMI Falls In April
|
Apr 23 |
Palisade Bio, Strand Life Sciences team up on colitis drug research
|
Apr 23 |
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
|
Apr 16 |
Palisade Bio stock rallies nearly 100% on colitis drug analysis
|
Apr 16 |
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
|